From ideas...to medical applications
In the absence of any straightforward laboratory tests, the most severe complication, known as type II heparin-induced thrombocytopenia (HIT) has...
From ideas...to medical applications
Midway between plasma haemostasis and cellular haemostasis are microparticles, rich in procoagulant phospholipids. An increase in this procoagulant...
From ideas...to medical applications
Listening to and exchanging ideas with members of the biomedical science community has enabled Stago to develop its expertise in the search for...
From ideas...to medical applications
Achieving a balanced policy with regard to investment in research & development (R&D), technological monitoring and rational acquisitions is a key...
January 23 - 26, 2012
February 2 - 4, 2012
April 25 - 28, 2012
STA®-Liatest® FM, the new marker for DIC
To better diagnose DIC and for a reliable vital prognosis, Stago has developed STA®-Liatest® FM, a new quantitative and fully-automated assay for fibrin monomers determination.
In 1977, with Bjarne Østerud, Dr. S.I. Rapaport described the activation of factor IX by factor VIIa/tissue factor complex as an additional pathway in the initiation of blood coagulation.
